| Name |
Number of Publications
|
Most Recent Publication
|
Publications by All Authors
|
Concept Score
|
Why?
|
|---|
| Rectal Neoplasms | 90 | 2022 | 1202 | 6.380 |
Why?
|
| Anus Neoplasms | 19 | 2023 | 411 | 2.100 |
Why?
|
| Colonic Neoplasms | 25 | 2021 | 1390 | 1.480 |
Why?
|
| Neoplasm Recurrence, Local | 48 | 2022 | 10035 | 1.420 |
Why?
|
| Fluorouracil | 30 | 2022 | 1944 | 1.290 |
Why?
|
| Colectomy | 11 | 2019 | 288 | 0.890 |
Why?
|
| Colorectal Neoplasms | 22 | 2023 | 3578 | 0.840 |
Why?
|
| Neoadjuvant Therapy | 29 | 2022 | 4975 | 0.840 |
Why?
|
| Adenocarcinoma | 33 | 2019 | 7789 | 0.820 |
Why?
|
| Chemoradiotherapy | 15 | 2022 | 1946 | 0.800 |
Why?
|
| Carcinoma, Squamous Cell | 15 | 2023 | 5437 | 0.740 |
Why?
|
| Neoplasm Staging | 63 | 2021 | 13658 | 0.740 |
Why?
|
| Combined Modality Therapy | 54 | 2019 | 8865 | 0.730 |
Why?
|
| Antimetabolites, Antineoplastic | 12 | 2006 | 1299 | 0.690 |
Why?
|
| Anal Canal | 13 | 2018 | 238 | 0.680 |
Why?
|
| Digestive System Surgical Procedures | 7 | 2017 | 275 | 0.620 |
Why?
|
| Lymphatic Metastasis | 24 | 2019 | 4844 | 0.560 |
Why?
|
| Chemotherapy, Adjuvant | 23 | 2016 | 3890 | 0.540 |
Why?
|
| Salvage Therapy | 8 | 2017 | 2054 | 0.530 |
Why?
|
| Medical Oncology | 10 | 2023 | 1423 | 0.510 |
Why?
|
| Radiotherapy, Adjuvant | 17 | 2014 | 2231 | 0.480 |
Why?
|
| Middle Aged | 112 | 2021 | 86204 | 0.470 |
Why?
|
| Aged | 95 | 2021 | 70117 | 0.440 |
Why?
|
| Pelvic Neoplasms | 5 | 2018 | 189 | 0.440 |
Why?
|
| Humans | 178 | 2023 | 261506 | 0.420 |
Why?
|
| Lymph Node Excision | 8 | 2019 | 1959 | 0.420 |
Why?
|
| Preoperative Care | 15 | 2016 | 1529 | 0.390 |
Why?
|
| Male | 114 | 2021 | 123000 | 0.390 |
Why?
|
| Positron Emission Tomography Computed Tomography | 1 | 2017 | 833 | 0.390 |
Why?
|
| Treatment Outcome | 46 | 2023 | 32848 | 0.370 |
Why?
|
| Antineoplastic Combined Chemotherapy Protocols | 28 | 2022 | 15862 | 0.370 |
Why?
|
| Postoperative Complications | 14 | 2023 | 5542 | 0.360 |
Why?
|
| Radiotherapy Dosage | 19 | 2013 | 3842 | 0.360 |
Why?
|
| Female | 115 | 2021 | 141928 | 0.360 |
Why?
|
| Quality of Life | 7 | 2014 | 4532 | 0.360 |
Why?
|
| Adult | 87 | 2021 | 77950 | 0.360 |
Why?
|
| Survival Rate | 28 | 2019 | 12221 | 0.360 |
Why?
|
| Retrospective Studies | 56 | 2023 | 37905 | 0.360 |
Why?
|
| Colostomy | 5 | 2018 | 70 | 0.320 |
Why?
|
| Follow-Up Studies | 31 | 2019 | 14889 | 0.320 |
Why?
|
| Chemoradiotherapy, Adjuvant | 7 | 2017 | 565 | 0.320 |
Why?
|
| Pelvic Exenteration | 6 | 2009 | 108 | 0.320 |
Why?
|
| Aged, 80 and over | 47 | 2018 | 29902 | 0.310 |
Why?
|
| Leucovorin | 7 | 2014 | 332 | 0.310 |
Why?
|
| Carcinoma | 6 | 2017 | 2578 | 0.300 |
Why?
|
| Prognosis | 33 | 2019 | 21713 | 0.300 |
Why?
|
| Rectum | 6 | 2018 | 467 | 0.290 |
Why?
|
| Surgical Oncology | 2 | 2020 | 190 | 0.280 |
Why?
|
| Disease-Free Survival | 20 | 2021 | 10001 | 0.270 |
Why?
|
| Re-Irradiation | 2 | 2018 | 163 | 0.270 |
Why?
|
| Ileostomy | 2 | 2018 | 46 | 0.270 |
Why?
|
| Neoplasm Metastasis | 13 | 2017 | 5112 | 0.260 |
Why?
|
| General Surgery | 2 | 2016 | 326 | 0.260 |
Why?
|
| Lymph Nodes | 7 | 2018 | 2967 | 0.260 |
Why?
|
| Insurance, Health | 1 | 2007 | 250 | 0.260 |
Why?
|
| Pain Management | 1 | 2010 | 668 | 0.250 |
Why?
|
| Neoplastic Syndromes, Hereditary | 1 | 2006 | 221 | 0.230 |
Why?
|
| Pain | 3 | 2010 | 1658 | 0.230 |
Why?
|
| SEER Program | 9 | 2015 | 1000 | 0.230 |
Why?
|
| Practice Guidelines as Topic | 6 | 2020 | 2403 | 0.230 |
Why?
|
| Survival Analysis | 20 | 2013 | 9180 | 0.220 |
Why?
|
| Genetic Markers | 1 | 2006 | 974 | 0.220 |
Why?
|
| Capecitabine | 9 | 2019 | 388 | 0.220 |
Why?
|
| Genetic Testing | 3 | 2022 | 1589 | 0.210 |
Why?
|
| Societies, Medical | 2 | 2018 | 1335 | 0.210 |
Why?
|
| Liver Neoplasms | 10 | 2023 | 4557 | 0.200 |
Why?
|
| Neoplasm, Residual | 5 | 2013 | 1656 | 0.200 |
Why?
|
| Health Services Accessibility | 1 | 2007 | 761 | 0.190 |
Why?
|
| Surgical Equipment | 1 | 2019 | 17 | 0.180 |
Why?
|
| Sacrum | 3 | 2009 | 132 | 0.180 |
Why?
|
| Cisplatin | 7 | 2022 | 2432 | 0.180 |
Why?
|
| Appointments and Schedules | 1 | 2020 | 98 | 0.180 |
Why?
|
| Deoxycytidine | 7 | 2014 | 1353 | 0.180 |
Why?
|
| Medical Errors | 2 | 2015 | 219 | 0.180 |
Why?
|
| Radiotherapy | 6 | 2011 | 1824 | 0.170 |
Why?
|
| Quality Improvement | 4 | 2019 | 851 | 0.170 |
Why?
|
| Fertility Preservation | 1 | 2021 | 150 | 0.170 |
Why?
|
| Adenocarcinoma, Mucinous | 3 | 2014 | 436 | 0.170 |
Why?
|
| Radiotherapy, Intensity-Modulated | 2 | 2022 | 2104 | 0.170 |
Why?
|
| DNA Mismatch Repair | 2 | 2021 | 268 | 0.170 |
Why?
|
| Prospective Studies | 13 | 2022 | 12873 | 0.160 |
Why?
|
| Survivors | 3 | 2014 | 1031 | 0.160 |
Why?
|
| Multivariate Analysis | 10 | 2016 | 4298 | 0.160 |
Why?
|
| Diffusion of Innovation | 1 | 2019 | 160 | 0.160 |
Why?
|
| Interleukin-2 | 5 | 1989 | 842 | 0.160 |
Why?
|
| Morbidity | 3 | 2014 | 397 | 0.160 |
Why?
|
| Young Adult | 18 | 2021 | 21445 | 0.160 |
Why?
|
| Laparoscopy | 4 | 2014 | 1225 | 0.150 |
Why?
|
| Intestinal Neoplasms | 1 | 2019 | 189 | 0.150 |
Why?
|
| Colorectal Neoplasms, Hereditary Nonpolyposis | 2 | 2015 | 469 | 0.150 |
Why?
|
| Radiotherapy, High-Energy | 1 | 1998 | 295 | 0.140 |
Why?
|
| Time Factors | 15 | 2017 | 12926 | 0.140 |
Why?
|
| Patient Handoff | 1 | 2016 | 39 | 0.140 |
Why?
|
| Perineum | 2 | 2001 | 107 | 0.140 |
Why?
|
| Intestine, Small | 1 | 2019 | 499 | 0.140 |
Why?
|
| Pelvis | 4 | 2019 | 362 | 0.130 |
Why?
|
| Postoperative Care | 2 | 2000 | 739 | 0.130 |
Why?
|
| Ki-67 Antigen | 2 | 2009 | 666 | 0.130 |
Why?
|
| Carcinoma, Signet Ring Cell | 3 | 2014 | 170 | 0.130 |
Why?
|
| Rectus Abdominis | 1 | 1995 | 100 | 0.130 |
Why?
|
| Defecation | 1 | 2014 | 58 | 0.130 |
Why?
|
| United States | 14 | 2018 | 15433 | 0.120 |
Why?
|
| Skin Transplantation | 1 | 1995 | 173 | 0.120 |
Why?
|
| Anastomosis, Surgical | 2 | 2013 | 371 | 0.120 |
Why?
|
| Biopsy | 7 | 2023 | 3443 | 0.120 |
Why?
|
| Incidence | 9 | 2018 | 5673 | 0.120 |
Why?
|
| Palliative Care | 4 | 2006 | 2037 | 0.120 |
Why?
|
| Risk Factors | 14 | 2019 | 17523 | 0.120 |
Why?
|
| Patient Safety | 1 | 2019 | 649 | 0.120 |
Why?
|
| Texas | 9 | 2020 | 6311 | 0.110 |
Why?
|
| Killer Cells, Natural | 3 | 1987 | 904 | 0.110 |
Why?
|
| Age Factors | 11 | 2013 | 5377 | 0.110 |
Why?
|
| Risk Assessment | 9 | 2015 | 6869 | 0.110 |
Why?
|
| Life Expectancy | 1 | 2013 | 129 | 0.110 |
Why?
|
| Magnetic Resonance Imaging | 5 | 2019 | 7702 | 0.110 |
Why?
|
| Kaplan-Meier Estimate | 7 | 2017 | 6207 | 0.110 |
Why?
|
| Antineoplastic Agents | 9 | 2019 | 14289 | 0.110 |
Why?
|
| Tumor Suppressor Protein p53 | 3 | 2006 | 3552 | 0.110 |
Why?
|
| Lymphocyte Activation | 3 | 1989 | 1688 | 0.110 |
Why?
|
| Coronavirus Infections | 1 | 2020 | 651 | 0.110 |
Why?
|
| Radiotherapy, Conformal | 1 | 2017 | 902 | 0.110 |
Why?
|
| Pneumonia, Viral | 1 | 2020 | 715 | 0.100 |
Why?
|
| Sexual Dysfunctions, Psychological | 1 | 2012 | 70 | 0.100 |
Why?
|
| Appendiceal Neoplasms | 1 | 2014 | 234 | 0.100 |
Why?
|
| Hepatectomy | 2 | 2023 | 1011 | 0.100 |
Why?
|
| Health Status Disparities | 1 | 2015 | 291 | 0.100 |
Why?
|
| Sex Factors | 7 | 2013 | 2139 | 0.100 |
Why?
|
| Organoplatinum Compounds | 5 | 2014 | 702 | 0.100 |
Why?
|
| Carcinoma, Neuroendocrine | 1 | 2017 | 716 | 0.100 |
Why?
|
| Sexual Dysfunction, Physiological | 1 | 2012 | 129 | 0.100 |
Why?
|
| Adolescent | 14 | 2021 | 31252 | 0.100 |
Why?
|
| Cohort Studies | 8 | 2015 | 9244 | 0.100 |
Why?
|
| Quality Indicators, Health Care | 1 | 2014 | 348 | 0.100 |
Why?
|
| Nomograms | 1 | 2013 | 313 | 0.100 |
Why?
|
| Neoplasms, Second Primary | 1 | 1999 | 1350 | 0.100 |
Why?
|
| Neoplasm Grading | 4 | 2017 | 1742 | 0.100 |
Why?
|
| Benchmarking | 3 | 2021 | 273 | 0.090 |
Why?
|
| Early Detection of Cancer | 2 | 2015 | 1258 | 0.090 |
Why?
|
| Biomarkers, Tumor | 4 | 2016 | 10331 | 0.090 |
Why?
|
| Cancer Care Facilities | 1 | 2014 | 884 | 0.090 |
Why?
|
| Communication | 1 | 2016 | 876 | 0.090 |
Why?
|
| Quality Assurance, Health Care | 1 | 2014 | 585 | 0.090 |
Why?
|
| Carcinoembryonic Antigen | 2 | 2007 | 222 | 0.080 |
Why?
|
| Metformin | 1 | 2013 | 378 | 0.080 |
Why?
|
| Neoplasm Invasiveness | 9 | 2015 | 3981 | 0.080 |
Why?
|
| Surgical Flaps | 3 | 2009 | 927 | 0.080 |
Why?
|
| Mucins | 1 | 2010 | 285 | 0.080 |
Why?
|
| Electronic Health Records | 1 | 2016 | 929 | 0.080 |
Why?
|
| Drug Administration Schedule | 5 | 2013 | 3472 | 0.080 |
Why?
|
| Proportional Hazards Models | 5 | 2016 | 4988 | 0.080 |
Why?
|
| Hypoglycemic Agents | 1 | 2013 | 586 | 0.080 |
Why?
|
| Health Status Indicators | 1 | 2009 | 224 | 0.080 |
Why?
|
| Stomach Neoplasms | 2 | 2018 | 2278 | 0.080 |
Why?
|
| Treatment Failure | 3 | 2008 | 1391 | 0.080 |
Why?
|
| Patient Selection | 5 | 2020 | 2055 | 0.080 |
Why?
|
| Disease Progression | 6 | 2017 | 6682 | 0.080 |
Why?
|
| Guideline Adherence | 2 | 2010 | 636 | 0.080 |
Why?
|
| Patient Care Team | 2 | 2018 | 795 | 0.080 |
Why?
|
| Robotics | 1 | 2012 | 359 | 0.080 |
Why?
|
| Abdomen, Acute | 1 | 1987 | 36 | 0.080 |
Why?
|
| Rehabilitation Nursing | 1 | 2007 | 9 | 0.080 |
Why?
|
| Spinal Fractures | 1 | 2009 | 132 | 0.080 |
Why?
|
| Surgical Instruments | 1 | 2008 | 138 | 0.080 |
Why?
|
| Radiation Injuries | 3 | 2017 | 1411 | 0.080 |
Why?
|
| Surgical Stomas | 1 | 2007 | 20 | 0.080 |
Why?
|
| Brachytherapy | 1 | 2014 | 977 | 0.070 |
Why?
|
| Spinal Neoplasms | 2 | 2005 | 631 | 0.070 |
Why?
|
| Social Adjustment | 1 | 2007 | 114 | 0.070 |
Why?
|
| Access to Information | 1 | 2007 | 65 | 0.070 |
Why?
|
| Watchful Waiting | 2 | 2019 | 289 | 0.070 |
Why?
|
| Hedgehog Proteins | 1 | 2009 | 424 | 0.070 |
Why?
|
| Camptothecin | 3 | 2017 | 517 | 0.070 |
Why?
|
| Endosonography | 2 | 2012 | 536 | 0.070 |
Why?
|
| Registries | 4 | 2014 | 2170 | 0.070 |
Why?
|
| Gastroenterostomy | 1 | 1985 | 5 | 0.070 |
Why?
|
| Liver Abscess | 1 | 1986 | 36 | 0.070 |
Why?
|
| Thallium | 1 | 1985 | 11 | 0.070 |
Why?
|
| Technetium | 1 | 1985 | 77 | 0.070 |
Why?
|
| Peutz-Jeghers Syndrome | 1 | 2006 | 56 | 0.070 |
Why?
|
| Tegafur | 3 | 2000 | 50 | 0.070 |
Why?
|
| Extremities | 1 | 1987 | 303 | 0.070 |
Why?
|
| Immunoenzyme Techniques | 3 | 2009 | 1165 | 0.070 |
Why?
|
| Granulomatous Disease, Chronic | 1 | 1986 | 79 | 0.070 |
Why?
|
| Uracil | 3 | 2000 | 64 | 0.070 |
Why?
|
| Neoplasm Proteins | 1 | 1997 | 3230 | 0.070 |
Why?
|
| Genes, bcl-2 | 1 | 2006 | 166 | 0.070 |
Why?
|
| Internship and Residency | 1 | 2016 | 1375 | 0.070 |
Why?
|
| Decision Making | 3 | 2020 | 1287 | 0.070 |
Why?
|
| Terminology as Topic | 1 | 2008 | 414 | 0.070 |
Why?
|
| Hyperparathyroidism | 1 | 1985 | 93 | 0.070 |
Why?
|
| Parathyroid Glands | 1 | 1985 | 127 | 0.060 |
Why?
|
| Radioisotopes | 1 | 1985 | 177 | 0.060 |
Why?
|
| Genetic Predisposition to Disease | 4 | 2016 | 5539 | 0.060 |
Why?
|
| Bevacizumab | 3 | 2014 | 938 | 0.060 |
Why?
|
| Induction Chemotherapy | 2 | 2018 | 669 | 0.060 |
Why?
|
| Obesity | 1 | 2017 | 2884 | 0.060 |
Why?
|
| Mitomycin | 2 | 2022 | 208 | 0.060 |
Why?
|
| Radiation-Sensitizing Agents | 1 | 2006 | 363 | 0.060 |
Why?
|
| Adenomatous Polyposis Coli | 1 | 2006 | 221 | 0.060 |
Why?
|
| Orthopedic Procedures | 1 | 2005 | 146 | 0.060 |
Why?
|
| Tomography, X-Ray Computed | 6 | 2012 | 7551 | 0.060 |
Why?
|
| Organ Sparing Treatments | 2 | 2017 | 277 | 0.060 |
Why?
|
| Activities of Daily Living | 1 | 2007 | 552 | 0.060 |
Why?
|
| Tumor Burden | 3 | 2017 | 1987 | 0.060 |
Why?
|
| Surgical Wound Infection | 1 | 1987 | 450 | 0.060 |
Why?
|
| Drainage | 1 | 1986 | 416 | 0.060 |
Why?
|
| Age of Onset | 2 | 2016 | 827 | 0.060 |
Why?
|
| Neoplasms | 7 | 2021 | 15193 | 0.060 |
Why?
|
| Feasibility Studies | 2 | 2019 | 2292 | 0.060 |
Why?
|
| Microsurgery | 1 | 2005 | 244 | 0.060 |
Why?
|
| Predictive Value of Tests | 4 | 2015 | 4892 | 0.050 |
Why?
|
| Nervous System Neoplasms | 1 | 2002 | 36 | 0.050 |
Why?
|
| Retreatment | 2 | 2017 | 452 | 0.050 |
Why?
|
| Positron-Emission Tomography | 2 | 2012 | 2173 | 0.050 |
Why?
|
| Sacrococcygeal Region | 1 | 2002 | 37 | 0.050 |
Why?
|
| Diabetes Mellitus, Type 2 | 1 | 2013 | 1362 | 0.050 |
Why?
|
| Brain | 1 | 1996 | 4113 | 0.050 |
Why?
|
| Risk | 3 | 2014 | 1972 | 0.050 |
Why?
|
| Ganglioneuroma | 1 | 2002 | 41 | 0.050 |
Why?
|
| Gastrointestinal Hemorrhage | 2 | 2001 | 340 | 0.050 |
Why?
|
| Intestinal Obstruction | 2 | 2001 | 202 | 0.050 |
Why?
|
| Operative Time | 1 | 2023 | 217 | 0.050 |
Why?
|
| Soft Tissue Neoplasms | 2 | 2000 | 882 | 0.050 |
Why?
|
| Genes, p53 | 2 | 1997 | 1090 | 0.050 |
Why?
|
| Socioeconomic Factors | 3 | 2013 | 1225 | 0.050 |
Why?
|
| NF-kappa B | 1 | 2009 | 1549 | 0.050 |
Why?
|
| Tissue Transplantation | 1 | 2001 | 35 | 0.050 |
Why?
|
| Databases, Factual | 3 | 2014 | 2218 | 0.050 |
Why?
|
| Infusions, Intravenous | 2 | 2003 | 1382 | 0.050 |
Why?
|
| Chi-Square Distribution | 4 | 2012 | 1323 | 0.050 |
Why?
|
| Viscera | 1 | 2001 | 81 | 0.050 |
Why?
|
| Urinary Bladder | 2 | 2005 | 575 | 0.050 |
Why?
|
| Biosimilar Pharmaceuticals | 1 | 2021 | 15 | 0.050 |
Why?
|
| Professional Staff Committees | 1 | 2001 | 30 | 0.050 |
Why?
|
| Adrenalectomy | 1 | 2001 | 188 | 0.050 |
Why?
|
| Contraindications | 1 | 2000 | 150 | 0.050 |
Why?
|
| Models, Economic | 1 | 2000 | 101 | 0.050 |
Why?
|
| Sentinel Lymph Node Biopsy | 1 | 2007 | 1415 | 0.050 |
Why?
|
| Neurosurgical Procedures | 1 | 2005 | 609 | 0.050 |
Why?
|
| Logistic Models | 3 | 2013 | 3441 | 0.050 |
Why?
|
| Regression Analysis | 2 | 2015 | 1546 | 0.050 |
Why?
|
| Reoperation | 3 | 2013 | 1382 | 0.050 |
Why?
|
| Randomized Controlled Trials as Topic | 2 | 2018 | 2594 | 0.050 |
Why?
|
| Adrenal Gland Neoplasms | 2 | 2001 | 489 | 0.050 |
Why?
|
| Tertiary Care Centers | 1 | 2022 | 403 | 0.040 |
Why?
|
| Postoperative Period | 2 | 2012 | 665 | 0.040 |
Why?
|
| Documentation | 1 | 2021 | 207 | 0.040 |
Why?
|
| Pancreatic Neoplasms | 6 | 2000 | 5061 | 0.040 |
Why?
|
| Recurrence | 4 | 2011 | 4758 | 0.040 |
Why?
|
| Cryosurgery | 1 | 2000 | 167 | 0.040 |
Why?
|
| Melanoma | 2 | 1996 | 5317 | 0.040 |
Why?
|
| Survivorship | 1 | 2019 | 109 | 0.040 |
Why?
|
| Disease Management | 2 | 2017 | 1052 | 0.040 |
Why?
|
| Sarcoma | 2 | 2000 | 1725 | 0.040 |
Why?
|
| Leukemia | 1 | 1987 | 1635 | 0.040 |
Why?
|
| Probability | 1 | 2000 | 866 | 0.040 |
Why?
|
| Brain Neoplasms | 1 | 1996 | 4849 | 0.040 |
Why?
|
| Microsatellite Instability | 1 | 2021 | 400 | 0.040 |
Why?
|
| Gastrointestinal Neoplasms | 2 | 2001 | 600 | 0.040 |
Why?
|
| Triage | 1 | 2020 | 252 | 0.040 |
Why?
|
| Fertility | 1 | 2021 | 336 | 0.040 |
Why?
|
| Patient Care Planning | 1 | 2000 | 297 | 0.040 |
Why?
|
| Actuarial Analysis | 1 | 1998 | 159 | 0.040 |
Why?
|
| Abdominal Neoplasms | 1 | 2000 | 231 | 0.040 |
Why?
|
| Research Design | 2 | 2007 | 1544 | 0.040 |
Why?
|
| Phorbol Esters | 2 | 1994 | 39 | 0.040 |
Why?
|
| Remission Induction | 2 | 2010 | 3569 | 0.040 |
Why?
|
| Videoconferencing | 1 | 2018 | 56 | 0.040 |
Why?
|
| Rosette Formation | 2 | 1987 | 38 | 0.040 |
Why?
|
| Radiodermatitis | 1 | 2017 | 75 | 0.040 |
Why?
|
| Consolidation Chemotherapy | 1 | 2017 | 155 | 0.040 |
Why?
|
| Antibodies, Monoclonal, Humanized | 3 | 2014 | 3251 | 0.040 |
Why?
|
| Drug Therapy, Combination | 2 | 2000 | 2315 | 0.040 |
Why?
|
| Chordoma | 1 | 1999 | 163 | 0.040 |
Why?
|
| Genes, MHC Class II | 1 | 1996 | 67 | 0.040 |
Why?
|
| Odds Ratio | 2 | 2014 | 2316 | 0.040 |
Why?
|
| HLA-DQ Antigens | 1 | 1996 | 58 | 0.040 |
Why?
|
| Angiogenesis Inhibitors | 2 | 2014 | 1248 | 0.040 |
Why?
|
| Longitudinal Studies | 2 | 2012 | 1945 | 0.040 |
Why?
|
| Analysis of Variance | 1 | 2001 | 2307 | 0.040 |
Why?
|
| Proliferating Cell Nuclear Antigen | 1 | 1997 | 195 | 0.030 |
Why?
|
| Prostatic Neoplasms | 2 | 2005 | 5767 | 0.030 |
Why?
|
| Etoposide | 1 | 2017 | 870 | 0.030 |
Why?
|
| Radiation Oncology | 1 | 2001 | 529 | 0.030 |
Why?
|
| Workflow | 1 | 2016 | 275 | 0.030 |
Why?
|
| Urethral Neoplasms | 1 | 1995 | 60 | 0.030 |
Why?
|
| Decision Support Techniques | 1 | 2000 | 622 | 0.030 |
Why?
|
| Gastrectomy | 1 | 2018 | 451 | 0.030 |
Why?
|
| Cell Separation | 2 | 1987 | 612 | 0.030 |
Why?
|
| Betacoronavirus | 1 | 2020 | 527 | 0.030 |
Why?
|
| Transcription Factors | 1 | 2009 | 5270 | 0.030 |
Why?
|
| Oxaloacetates | 1 | 2014 | 7 | 0.030 |
Why?
|
| Carcinoid Tumor | 1 | 1997 | 280 | 0.030 |
Why?
|
| Carboplatin | 1 | 2017 | 823 | 0.030 |
Why?
|
| Intraoperative Care | 1 | 1996 | 259 | 0.030 |
Why?
|
| Administration, Oral | 3 | 2006 | 1544 | 0.030 |
Why?
|
| Hemodynamics | 2 | 1989 | 935 | 0.030 |
Why?
|
| Adenoviridae | 2 | 1996 | 1459 | 0.030 |
Why?
|
| Organs at Risk | 1 | 2017 | 514 | 0.030 |
Why?
|
| Carcinoma, Islet Cell | 1 | 1993 | 35 | 0.030 |
Why?
|
| Early Termination of Clinical Trials | 1 | 2013 | 85 | 0.030 |
Why?
|
| Diarrhea | 1 | 2017 | 686 | 0.030 |
Why?
|
| Cross-Sectional Studies | 2 | 2014 | 4314 | 0.030 |
Why?
|
| Sex Distribution | 1 | 2015 | 495 | 0.030 |
Why?
|
| Confidence Intervals | 1 | 2015 | 756 | 0.030 |
Why?
|
| Age Distribution | 1 | 2015 | 698 | 0.030 |
Why?
|
| Elective Surgical Procedures | 1 | 2014 | 250 | 0.030 |
Why?
|
| Clinical Decision-Making | 1 | 2016 | 524 | 0.030 |
Why?
|
| Drug Resistance | 1 | 1994 | 587 | 0.030 |
Why?
|
| Population Surveillance | 1 | 2016 | 627 | 0.030 |
Why?
|
| Cetuximab | 1 | 2014 | 472 | 0.030 |
Why?
|
| Proctoscopy | 1 | 2012 | 17 | 0.030 |
Why?
|
| Protein Kinase C | 1 | 1994 | 396 | 0.030 |
Why?
|
| Reproducibility of Results | 2 | 2013 | 6009 | 0.030 |
Why?
|
| Erlotinib Hydrochloride | 1 | 2013 | 388 | 0.030 |
Why?
|
| Comprehensive Health Care | 1 | 2012 | 49 | 0.030 |
Why?
|
| GTP Phosphohydrolases | 1 | 2014 | 336 | 0.030 |
Why?
|
| Genetic Therapy | 2 | 1996 | 1616 | 0.030 |
Why?
|
| Isoenzymes | 1 | 1994 | 614 | 0.030 |
Why?
|
| Gels | 1 | 2012 | 105 | 0.030 |
Why?
|
| Signal-To-Noise Ratio | 1 | 2012 | 117 | 0.030 |
Why?
|
| Telemedicine | 1 | 2018 | 471 | 0.030 |
Why?
|
| Sensitivity and Specificity | 3 | 2007 | 4971 | 0.030 |
Why?
|
| Transfection | 1 | 1996 | 2944 | 0.020 |
Why?
|
| Peritoneum | 1 | 2012 | 150 | 0.020 |
Why?
|
| Muscle, Smooth | 1 | 2012 | 236 | 0.020 |
Why?
|
| Genetic Vectors | 1 | 1996 | 1694 | 0.020 |
Why?
|
| Surveys and Questionnaires | 2 | 2014 | 5687 | 0.020 |
Why?
|
| Algorithms | 2 | 2013 | 3890 | 0.020 |
Why?
|
| Pandemics | 1 | 2020 | 1559 | 0.020 |
Why?
|
| Germ-Line Mutation | 1 | 2016 | 1046 | 0.020 |
Why?
|
| Blood Vessels | 1 | 2012 | 217 | 0.020 |
Why?
|
| Receptors, Cell Surface | 1 | 1994 | 862 | 0.020 |
Why?
|
| Maintenance Chemotherapy | 1 | 2011 | 202 | 0.020 |
Why?
|
| Vitamin D | 1 | 2012 | 261 | 0.020 |
Why?
|
| Guidelines as Topic | 1 | 2012 | 383 | 0.020 |
Why?
|
| Maximum Tolerated Dose | 1 | 2013 | 1290 | 0.020 |
Why?
|
| Erectile Dysfunction | 1 | 2012 | 212 | 0.020 |
Why?
|
| Wound Healing | 1 | 1995 | 815 | 0.020 |
Why?
|
| Patient Readmission | 1 | 2014 | 548 | 0.020 |
Why?
|
| Diagnosis, Differential | 1 | 2019 | 4744 | 0.020 |
Why?
|
| ras Proteins | 1 | 2014 | 770 | 0.020 |
Why?
|
| Statistics, Nonparametric | 2 | 2006 | 980 | 0.020 |
Why?
|
| Proctocolectomy, Restorative | 1 | 2009 | 20 | 0.020 |
Why?
|
| Diffusion Magnetic Resonance Imaging | 1 | 2012 | 341 | 0.020 |
Why?
|
| Body Mass Index | 1 | 2017 | 2203 | 0.020 |
Why?
|
| Social Support | 1 | 2012 | 560 | 0.020 |
Why?
|
| Continuity of Patient Care | 1 | 2011 | 225 | 0.020 |
Why?
|
| Medicare | 1 | 2014 | 860 | 0.020 |
Why?
|
| Zinc Finger Protein GLI1 | 1 | 2009 | 111 | 0.020 |
Why?
|
| Artifacts | 1 | 2012 | 532 | 0.020 |
Why?
|
| Minimally Invasive Surgical Procedures | 1 | 2012 | 500 | 0.020 |
Why?
|
| Quinazolines | 1 | 2013 | 923 | 0.020 |
Why?
|
| ROC Curve | 1 | 2012 | 1183 | 0.020 |
Why?
|
| Medical Audit | 1 | 2009 | 188 | 0.020 |
Why?
|
| Cell Division | 2 | 1996 | 2489 | 0.020 |
Why?
|
| Surgical Wound Dehiscence | 1 | 2009 | 129 | 0.020 |
Why?
|
| Thigh | 1 | 2009 | 172 | 0.020 |
Why?
|
| Cecal Diseases | 1 | 1987 | 13 | 0.020 |
Why?
|
| Prostatectomy | 2 | 2005 | 962 | 0.020 |
Why?
|
| Quality Control | 1 | 2009 | 457 | 0.020 |
Why?
|
| Multimodal Imaging | 1 | 2012 | 550 | 0.020 |
Why?
|
| Evaluation Studies as Topic | 2 | 1985 | 418 | 0.020 |
Why?
|
| Proto-Oncogene Proteins p21(ras) | 1 | 2014 | 1331 | 0.020 |
Why?
|
| Cytotoxicity Tests, Immunologic | 1 | 1987 | 84 | 0.020 |
Why?
|
| Rosaniline Dyes | 1 | 2007 | 108 | 0.020 |
Why?
|
| Mitogens | 1 | 1987 | 75 | 0.020 |
Why?
|
| CD2 Antigens | 1 | 1987 | 31 | 0.020 |
Why?
|
| Proto-Oncogene Proteins B-raf | 1 | 2014 | 1283 | 0.020 |
Why?
|
| Medical Records | 1 | 2008 | 415 | 0.020 |
Why?
|
| Matched-Pair Analysis | 1 | 2006 | 103 | 0.020 |
Why?
|
| HLA-DR Antigens | 1 | 1987 | 173 | 0.020 |
Why?
|
| Imaging, Three-Dimensional | 1 | 2012 | 925 | 0.020 |
Why?
|
| Antigens, Differentiation, T-Lymphocyte | 1 | 1987 | 167 | 0.020 |
Why?
|
| Keratins | 1 | 2007 | 330 | 0.020 |
Why?
|
| Cell Differentiation | 1 | 1997 | 4078 | 0.020 |
Why?
|
| Linear Models | 1 | 2009 | 1085 | 0.020 |
Why?
|
| Vagotomy | 1 | 1985 | 26 | 0.020 |
Why?
|
| Survival | 1 | 2006 | 177 | 0.020 |
Why?
|
| Celecoxib | 1 | 2006 | 200 | 0.020 |
Why?
|
| Appendicitis | 1 | 1987 | 169 | 0.020 |
Why?
|
| Biopsy, Needle | 1 | 2010 | 1363 | 0.020 |
Why?
|
| Computers | 1 | 1985 | 141 | 0.020 |
Why?
|
| Subtraction Technique | 1 | 1985 | 141 | 0.020 |
Why?
|
| Safety | 1 | 2007 | 465 | 0.020 |
Why?
|
| Contrast Media | 1 | 2012 | 1472 | 0.020 |
Why?
|
| Receptors, Immunologic | 1 | 1987 | 309 | 0.020 |
Why?
|
| Immunization, Passive | 1 | 1985 | 172 | 0.020 |
Why?
|
| Proto-Oncogene Proteins | 1 | 2014 | 2488 | 0.020 |
Why?
|
| Internet | 1 | 2009 | 706 | 0.020 |
Why?
|
| Fluorescent Antibody Technique | 1 | 1987 | 1062 | 0.020 |
Why?
|
| Lung Neoplasms | 4 | 2017 | 11538 | 0.020 |
Why?
|
| Radionuclide Imaging | 1 | 1985 | 660 | 0.020 |
Why?
|
| Transplantation, Heterologous | 2 | 1996 | 1082 | 0.020 |
Why?
|
| Hospitalization | 1 | 2013 | 2083 | 0.020 |
Why?
|
| In Vitro Techniques | 1 | 1987 | 1618 | 0.010 |
Why?
|
| Parathyroid Neoplasms | 1 | 1985 | 185 | 0.010 |
Why?
|
| Cell Adhesion | 1 | 1987 | 1008 | 0.010 |
Why?
|
| Washington | 1 | 2003 | 70 | 0.010 |
Why?
|
| Membrane Proteins | 1 | 2014 | 2819 | 0.010 |
Why?
|
| Tumor Cells, Cultured | 3 | 1996 | 5395 | 0.010 |
Why?
|
| Lung Diseases | 1 | 1989 | 717 | 0.010 |
Why?
|
| Walking | 1 | 2005 | 277 | 0.010 |
Why?
|
| Colonic Polyps | 1 | 2005 | 209 | 0.010 |
Why?
|
| Pilot Projects | 2 | 2003 | 2803 | 0.010 |
Why?
|
| Case-Control Studies | 1 | 2012 | 6100 | 0.010 |
Why?
|
| Acute Disease | 1 | 1987 | 2422 | 0.010 |
Why?
|
| Pyridines | 1 | 2009 | 1244 | 0.010 |
Why?
|
| Peripheral Nervous System Diseases | 1 | 2006 | 393 | 0.010 |
Why?
|
| Muscle, Skeletal | 1 | 2009 | 1270 | 0.010 |
Why?
|
| Heart | 1 | 1988 | 1223 | 0.010 |
Why?
|
| Comorbidity | 1 | 2008 | 2352 | 0.010 |
Why?
|
| Sympathetic Nervous System | 1 | 2002 | 159 | 0.010 |
Why?
|
| Pubic Bone | 1 | 2000 | 16 | 0.010 |
Why?
|
| Fluorodeoxyglucose F18 | 1 | 2007 | 1226 | 0.010 |
Why?
|
| Osteitis | 1 | 2000 | 17 | 0.010 |
Why?
|
| Organizational Objectives | 1 | 2001 | 61 | 0.010 |
Why?
|
| Practice Patterns, Physicians' | 1 | 2009 | 1303 | 0.010 |
Why?
|
| Mutation | 1 | 2021 | 15179 | 0.010 |
Why?
|
| Intestines | 1 | 2005 | 686 | 0.010 |
Why?
|
| Adenoma | 1 | 1985 | 716 | 0.010 |
Why?
|
| Urologic Diseases | 1 | 2000 | 78 | 0.010 |
Why?
|
| Cell Transformation, Neoplastic | 1 | 2009 | 2359 | 0.010 |
Why?
|
| Academic Medical Centers | 1 | 2003 | 672 | 0.010 |
Why?
|
| Mice, Nude | 2 | 1996 | 4307 | 0.010 |
Why?
|
| Oncology Service, Hospital | 1 | 1999 | 48 | 0.010 |
Why?
|
| Lymphoma | 1 | 2007 | 1467 | 0.010 |
Why?
|
| Carrier Proteins | 1 | 1987 | 2022 | 0.010 |
Why?
|
| Peritoneal Neoplasms | 1 | 1985 | 821 | 0.010 |
Why?
|
| Forecasting | 1 | 2001 | 694 | 0.010 |
Why?
|
| Retroperitoneal Neoplasms | 1 | 2000 | 262 | 0.010 |
Why?
|
| Inflammation | 1 | 1987 | 2522 | 0.010 |
Why?
|
| Colon | 1 | 2001 | 670 | 0.010 |
Why?
|
| Pyrazoles | 1 | 2006 | 1471 | 0.010 |
Why?
|
| Sulfonamides | 1 | 2006 | 1823 | 0.010 |
Why?
|
| Ploidies | 1 | 1997 | 248 | 0.010 |
Why?
|
| Surgical Procedures, Operative | 1 | 2000 | 383 | 0.010 |
Why?
|
| HLA-DQ alpha-Chains | 1 | 1996 | 23 | 0.010 |
Why?
|
| HLA-DQ beta-Chains | 1 | 1996 | 34 | 0.010 |
Why?
|
| Child | 2 | 1987 | 29154 | 0.010 |
Why?
|
| Antibodies, Monoclonal | 1 | 2009 | 4367 | 0.010 |
Why?
|
| In Situ Nick-End Labeling | 1 | 1996 | 448 | 0.010 |
Why?
|
| Cause of Death | 1 | 1999 | 752 | 0.010 |
Why?
|
| Cardiovascular Diseases | 1 | 1989 | 2195 | 0.010 |
Why?
|
| Clinical Trials as Topic | 2 | 2001 | 3719 | 0.010 |
Why?
|
| ATP-Binding Cassette Transporters | 1 | 1996 | 299 | 0.010 |
Why?
|
| Cost-Benefit Analysis | 1 | 1998 | 945 | 0.010 |
Why?
|
| Receptors, Urokinase Plasminogen Activator | 1 | 1994 | 107 | 0.010 |
Why?
|
| Cell Death | 1 | 1996 | 671 | 0.010 |
Why?
|
| Prostate | 1 | 1999 | 1088 | 0.010 |
Why?
|
| Immunotherapy | 1 | 1987 | 3341 | 0.010 |
Why?
|
| Genes | 1 | 1994 | 491 | 0.010 |
Why?
|
| Gene Transfer Techniques | 1 | 1996 | 716 | 0.010 |
Why?
|
| Gene Frequency | 1 | 1996 | 1163 | 0.010 |
Why?
|
| Enzyme-Linked Immunosorbent Assay | 1 | 1996 | 1489 | 0.010 |
Why?
|
| Neoplasms, Experimental | 1 | 1996 | 750 | 0.010 |
Why?
|
| Immunoglobulin G | 1 | 1996 | 1021 | 0.010 |
Why?
|
| Dose-Response Relationship, Drug | 1 | 2000 | 4938 | 0.010 |
Why?
|
| RNA, Neoplasm | 1 | 1994 | 771 | 0.010 |
Why?
|
| Gene Amplification | 1 | 1994 | 731 | 0.010 |
Why?
|
| Child, Preschool | 1 | 1987 | 16273 | 0.010 |
Why?
|
| Enzyme Activation | 1 | 1994 | 1764 | 0.010 |
Why?
|
| Cell Survival | 1 | 1996 | 3045 | 0.010 |
Why?
|
| Pancreaticoduodenectomy | 1 | 1993 | 690 | 0.010 |
Why?
|
| Carcinoma, Non-Small-Cell Lung | 1 | 2007 | 5319 | 0.010 |
Why?
|
| Gene Expression Regulation, Neoplastic | 2 | 1996 | 8873 | 0.010 |
Why?
|
| Pancreatectomy | 1 | 1993 | 652 | 0.010 |
Why?
|
| Cardiac Volume | 1 | 1988 | 18 | 0.010 |
Why?
|
| Lymphokines | 1 | 1989 | 272 | 0.000 |
Why?
|
| Cardiac Output | 1 | 1988 | 194 | 0.000 |
Why?
|
| Vascular Resistance | 1 | 1988 | 200 | 0.000 |
Why?
|
| Ultrasonography | 1 | 1994 | 1863 | 0.000 |
Why?
|
| Shock, Septic | 1 | 1988 | 181 | 0.000 |
Why?
|
| Helicobacter pylori | 1 | 1996 | 1295 | 0.000 |
Why?
|
| Transcription, Genetic | 1 | 1994 | 3154 | 0.000 |
Why?
|
| Stroke Volume | 1 | 1988 | 577 | 0.000 |
Why?
|
| Leukapheresis | 1 | 1985 | 152 | 0.000 |
Why?
|
| Mice | 2 | 1996 | 34495 | 0.000 |
Why?
|
| Heart Rate | 1 | 1988 | 737 | 0.000 |
Why?
|
| RNA, Messenger | 1 | 1994 | 6150 | 0.000 |
Why?
|
| Gangrene | 1 | 1984 | 28 | 0.000 |
Why?
|
| Enteritis | 1 | 1984 | 65 | 0.000 |
Why?
|
| Breast Neoplasms | 1 | 2007 | 15694 | 0.000 |
Why?
|
| Blood Pressure | 1 | 1988 | 1467 | 0.000 |
Why?
|
| Apoptosis | 1 | 1996 | 7591 | 0.000 |
Why?
|
| Intraoperative Period | 1 | 1982 | 246 | 0.000 |
Why?
|
| Animals | 2 | 1996 | 59536 | 0.000 |
Why?
|
| Pancreatic Diseases | 1 | 1982 | 108 | 0.000 |
Why?
|
| Transplantation, Autologous | 1 | 1985 | 1914 | 0.000 |
Why?
|
| Recombinant Proteins | 1 | 1985 | 2927 | 0.000 |
Why?
|
| Carcinoma, Renal Cell | 1 | 1985 | 2326 | 0.000 |
Why?
|
| Kidney Neoplasms | 1 | 1985 | 3022 | 0.000 |
Why?
|